Search

Displaying results 5731 - 5740 of 10000 in total
  1. Drug

    Otelixizumab

    go.drugbank.com/drugs/DB05496
    Investigational

    and inhibit autoreactive disease activity. … Tolerx is developing otelixizumab to treat patients with type 1 diabetes, psoriasis and other autoimmune diseases such as rheumatoid arthritis.

    Categories: Amino Acids, Peptides, and Proteins
  2. Drug

    Medetomidine

    go.drugbank.com/drugs/DB11428
    ExperimentalVet approved

    Medetomidine is an intravenously available alpha-2 adrenergic agonist. The drug has been developed by Orion Pharma. … In the United States, it is currently approved for its veterinary use in dogs and distributed by Pfizer Animal Health. In Canada, medetomidine is distributed by Novartis Animal Health.

    Categories: Hypnotics and Sedatives
  3. Drug

    SNS-314

    go.drugbank.com/drugs/DB06134
    Investigational

    SNS-314 inhibits tumor growth in a variety of preclinical models, and it is now being tested in single agent Phase 1 studies in patients with advanced solid tumours. … SNS-314 is a potent and selective inhibitor of Aurora kinases A, B, and C.

  4. Drug

    AVAC

    go.drugbank.com/drugs/DB05441
    Experimental

    AVAC is derived from M. vaccae. It has been tested in uses related to asthma and in treating eczema and atopic dermatitis. … [Mycobacterium vaccae] is a non-pathogenic, saprophytic bacteria whose antigens can be used to induce peripheral immune activation through the activity of regulatory T-cells that surpress inappropriate

  5. Drug

    Vanoxerine

    go.drugbank.com/drugs/DB03701
    Investigational

    [A248555] Vanoxerine is an investigational drug and has not been approved for therapeutic use. … Vanoxerine is a highly selective dopamine transporter antagonist. It was synthesized in the late 1970s and developed as a potential treatment for depression.

  6. Drug

    SARS-CoV-2 Sclamp

    go.drugbank.com/drugs/DB15849
    Investigational

    The University of Queensland (UQ), in partnership with The Coalition for Epidemic Preparedeness Inovations (CEPI) and CSL has developed a COVID-19 candidate, SARS-CoV-2 Sclamp. … As of July 13, 2020, the candidate is being tested for safety and immunogenicity in Phase 1 clinical trials in Queensland (ACTRN12620000674932).

    Synonyms: UQ COVID-19 Vaccine, UQ-1-SARS-CoV-2-Sclamp
  7. Drug

    Famprofazone

    go.drugbank.com/drugs/DB16702
    Experimental

    [L34724] It is important to note that the drug is metabolized to [methamphetamine] and [amphetamine] in the body and can lead to positive tests results for illicit drug use. … [A236369,L34724] Famprofazone is included in the list of prohibited substances specified by the ‘World Anti-Doping Agency’ (WADA).[L34729]

  8. Drug

    Tasosartan

    go.drugbank.com/drugs/DB01349
    Experimental

    It is used to treat patients with essential hypertension. … Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. Its long duration of action has been attributed to its active metabolite enoltasosartan.

    Categories: Angiotensin II receptor blockers (ARBs), plain, Agents Acting on the Renin-Angiotensin System
  9. Drug

    HZT-501

    go.drugbank.com/drugs/DB05369
    Investigational

    HZT-501 is under investigation by Horizon Therapeutics, Inc., a privately held biopharmaceutical company. … It has entered Phase 3 clinical trials in March 2007 for reduction of the risk of development of ibuprofen-associated upper gastrointestinal (i.e., gastric and/or duodenal) ulcers.

  10. Drug

    Arylacenamide

    go.drugbank.com/drugs/DB05792
    Experimental

    Arylacenamide (SR31747) is a peripheral [sigma] ligand that binds four proteins in human cells, i.e. SRBP-1, [sigma]-2, HSI and its relative SRBP-2. … It is a dual agent with both immunomodulatory and antiproliferative activities.